Fig. 4

Association of sSIGLEC-1 with ancestry and serological markers of SLE. a Scatter plots depict the frequency (geometric mean ± 95% CI) of sSIGLEC-1 concentrations in healthy donors (N = 504) and SLE patients (N = 75). Red diamonds, 24 healthy donors and 34 SLE patients from cohort 1 for which we have generated additional immunophenotyping and transcriptional data. P value was calculated using a two-tailed non-parametric Mann–Whitney test. b Scatter plots depict the frequency (geometric mean ± 95% CI) of sSIGLEC-1 concentrations in serum samples from a cohort of 99 systemic sclerosis (SSc) patients (red) and 50 healthy donors (black). SSc patients were stratified into patients displaying limited (N = 50) or diffuse (N = 49) cutaneous disease manifestation. c Histograms depict the distribution of sSIGLEC-1 concentrations in European and non-European SLE patients from cohort 3. d Box plots depict the distribution of sSIGLEC-1 concentrations in SLE patients stratified by ancestry group. Mean sSIGLEC-1 levels are indicated for each population. Twenty-three patients of additional minor ancestry groups (including Middle Eastern, Maori and Fiji) were included in the non-European population for the combined analysis. P values were calculated using Pearson’s chi-squared test comparing the concentration of sSIGLEC-1 in patients of non-European and European ancestry. e Association between sSIGLEC-1 concentrations and serum complement component 3 (C3) levels. P value was calculated by linear regression. **P < 0.01. AFR African/Afro-Caribbean, EAS East Asian, EUR European, SAS South East Asian, SLE systemic lupus erythematosus, SSc systemic sclerosis, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1